38580-82-4

Basic information

• Product Name: 1,1'-BIPHENYL, 3-(CHLOROMETHYL)-
• Synonyms: 1,1'-BIPHENYL, 3-(CHLOROMETHYL)-;3-(chloroMethyl)biphenyl;3-(ChloroMethyl)-1,1'-biphenyl
• CAS NO: 38580-82-4
• Molecular Formula: C₁₃H₁₁Cl
• Molecular Weight: 202.67944
• Mol File: 38580-82-4.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 317.63 °C at 760 mmHg
• Flash Point: 140.608 °C
• Appearance: /
• Density: 1.111 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,1'-BIPHENYL, 3-(CHLOROMETHYL)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1'-BIPHENYL, 3-(CHLOROMETHYL)-(38580-82-4)
• EPA Substance Registry System: 1,1'-BIPHENYL, 3-(CHLOROMETHYL)-(38580-82-4)

Safety Data

• Hazardous Substances Data: 38580-82-4(Hazardous Substances Data)

Usage

General Description

1,1'-Biphenyl, 3-(chloromethyl)- is a chemical compound with the molecular formula C13H11Cl. It is a chlorinated derivative of biphenyl, which is composed of two benzene rings connected by a single carbon-carbon bond. The presence of the chloromethyl group makes this compound useful for various applications, such as in the synthesis of pharmaceuticals, dyes, and other organic compounds. It is also used as a building block in the production of polymers and plastics. The chemical's structure and properties make it a versatile and important compound in the field of organic chemistry and industrial manufacturing.

Upstream product

• 69605-90-9 3-phenyl-benzyl alcohol 
• 716-76-7 3-phenylbenzoic acid 
• 16606-00-1 methyl 3-phenylbenzoate 
• 98-80-6 phenylboronic acid 
• 15852-73-0 (3-Bromophenyl)methanol 
• 108-86-1 bromobenzene 
• 1204-60-0 biphenyl-3-carbaldehyde 
• 87199-16-4 3-Formylphenylboronic acid 
• 932-77-4 3-bromobenzyl chloride 
• 19926-50-2 biphenyl-3-carboxylic acid ethyl ester 

Downstream Products

• 655233-62-8 5,6-bis-(biphenyl-3-ylmethoxy)-3-chloro-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 172732-88-6 1-((1,1'-biphenyl)-3-ylmethyl)-2-methyl-4-methoxy-1H-indole 
• 790-22-7 3-benzyl-1,1'-biphenyl 

Relevant articles and documents

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE

This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to compounds, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.

Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1) has emerged as an attractive anti-diabetic target that mediates glucose-stimulated insulin secretion. Several FFA1 agonists have been reported, but many of them possessed somewhat high lipophilicity and/or molecular weight. Herein, we describe the identification of sulfone-carboxylic acid moiety with the multiple advantages of reducing lipophilicity, cytotoxicity and β-oxidation associated with compound 2. Further structure-activity relationship study based on the previleged scaffolds led to the discovery of 2-{(4-[(2’-chloro-[1,1’-biphenyl]-3-yl)methoxy]phenyl)sulfonyl}acetic acid (compound 20), which showed a better balance than compound 2 in terms of physicochemical properties, cytotoxicity profiles and pharmacokinetic properties. Subsequent in vivo studies demonstrated that compound 20 robustly improves the glucose tolerance both in normal and type 2 diabetic models without the risk of hypoglycemia. Compared to the high risk of TAK-875 induced liver toxicity, there was no significant adverse effects such as hepatic and renal toxicity were observed in the chronic toxicity studies of compound 20 even at the higher dose.